Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
$12.49
+1.5%
$7.22
$3.72
$12.97
$1.42B1.882.03 million shs2.33 million shs
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$65.35
+0.0%
$45.23
$30.04
$71.13
$5.64B1.822.54 million shs3.45 million shs
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
$37.73
+2.1%
$33.19
$29.31
$61.38
$4.52B0.591.53 million shs745,322 shs
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
$35.71
+0.2%
$33.84
$27.66
$121.06
$4.60B1.191.49 million shs418,694 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
-1.52%+10.91%+70.12%+183.41%+42.86%
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
+0.31%+15.79%+47.64%+66.53%+19.74%
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
-0.73%-4.20%+13.97%-2.25%-34.48%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-1.57%-2.03%+8.43%+14.01%-56.34%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
3.4168 of 5 stars
4.43.00.00.02.21.70.6
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
2.8593 of 5 stars
3.31.00.00.03.83.30.6
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
4.1144 of 5 stars
4.51.00.04.62.60.80.0
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
1.8523 of 5 stars
3.61.00.00.02.51.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
2.82
Moderate Buy$18.7049.77% Upside
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
2.53
Moderate Buy$71.319.12% Upside
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
2.93
Moderate Buy$70.9287.97% Upside
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
3.10
Buy$136.50282.21% Upside

Current Analyst Ratings Breakdown

Latest COGT, CRSP, PCVX, and CYTK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/22/2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$79.00 ➝ $78.00
7/18/2025
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$15.00 ➝ $22.00
7/10/2025
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$25.00 ➝ $29.00
7/8/2025
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$12.00 ➝ $22.00
7/8/2025
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$17.00
7/8/2025
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$7.00 ➝ $9.00
7/8/2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$81.00
7/7/2025
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$23.00 ➝ $28.00
7/7/2025
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$16.00 ➝ $18.00
6/30/2025
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral$10.00
6/27/2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$105.00
(Data available from 7/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
N/AN/AN/AN/A$1.32 per shareN/A
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$35M161.26N/AN/A$22.64 per share2.89
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
$18.47M243.97N/AN/A($1.15) per share-32.81
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/AN/AN/AN/A$26.52 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
-$255.86M-$1.84N/AN/AN/AN/A-149.79%-75.61%8/5/2025 (Estimated)
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-$366.25M-$4.52N/AN/AN/A-1,023.64%-20.08%-17.13%8/4/2025 (Estimated)
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
-$589.53M-$5.29N/AN/AN/A-3,201.47%N/A-43.75%8/6/2025 (Estimated)
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-$463.93M-$3.99N/AN/AN/AN/A-17.12%-16.26%8/5/2025 (Estimated)

Latest COGT, CRSP, PCVX, and CYTK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
-$1.32N/AN/AN/AN/AN/A
8/5/2025Q2 2025
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
-$0.54N/AN/AN/AN/AN/A
8/5/2025Q2 2025
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-$1.12N/AN/AN/AN/AN/A
8/4/2025Q2 2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-$1.54N/AN/AN/A$6.44 millionN/A
5/14/2025Q1 2025
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-$1.02-$1.04-$0.02-$1.04N/AN/A
5/6/2025Q1 2025
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
-$0.56-$0.52+$0.04-$0.52N/AN/A
5/6/2025Q1 2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-$1.27-$1.58-$0.31-$1.58N/AN/A
5/6/2025Q1 2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
-$1.41-$1.36+$0.05-$1.36$2.77 million$1.60 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
N/AN/AN/AN/AN/A
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
N/AN/AN/AN/AN/A
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/AN/AN/AN/AN/A
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
N/A
5.13
5.13
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
N/A
15.64
15.64
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/A
5.99
5.99
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/A
17.70
17.70

Institutional Ownership

CompanyInstitutional Ownership
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
N/A
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
69.20%
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/A
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
96.78%

Insider Ownership

CompanyInsider Ownership
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
7.29%
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
4.30%
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
3.40%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
3.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
80113.86 million105.56 millionOptionable
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
46086.36 million82.82 millionOptionable
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
250119.43 million115.37 millionOptionable
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
160129.00 million125.01 millionOptionable

Recent News About These Companies

Mizuho Maintains an Overweight Rating on Vaxcyte (PCVX)
Vaxcyte: Sentiment Is Pushing The Shares Down
Vaxcyte appoints new independent director

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cogent Biosciences stock logo

Cogent Biosciences NASDAQ:COGT

$12.48 +0.18 (+1.50%)
As of 03:56 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

CRISPR Therapeutics stock logo

CRISPR Therapeutics NASDAQ:CRSP

$65.67 +0.34 (+0.53%)
As of 03:56 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Cytokinetics stock logo

Cytokinetics NASDAQ:CYTK

$37.73 +0.77 (+2.09%)
As of 03:56 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Vaxcyte stock logo

Vaxcyte NASDAQ:PCVX

$35.72 +0.08 (+0.22%)
As of 03:56 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.